학술논문

Exploratory analysis of the platelet-to-lymphocyte ratio prognostic value in the adjuvant renal cell cancer setting
Document Type
article
Source
Future Oncology. 17(4)
Subject
Biomedical and Clinical Sciences
Clinical Sciences
Oncology and Carcinogenesis
Kidney Disease
Cancer
Clinical Trials and Supportive Activities
Clinical Research
Evaluation of treatments and therapeutic interventions
6.1 Pharmaceuticals
Adult
Aged
Aged
80 and over
Blood Platelets
Carcinoma
Renal Cell
Disease-Free Survival
Female
Humans
Kidney Neoplasms
Lymphocytes
Male
Middle Aged
Young Adult
adjuvant
lymphocyte
platelet
prognostic
renal cell carcinoma
sunitinib
Oncology & Carcinogenesis
Oncology and carcinogenesis
Language
Abstract
Aim: To examine the prognostic value of the platelet-to-lymphocyte ratio (PLR) in the adjuvant renal cell carcinoma setting. Materials & methods: Patients received adjuvant sunitinib (50 mg/day; 4 weeks on/2 weeks off) or placebo. The primary end point was disease-free survival (DFS). Results: In 609 patients, DFS was similar for baseline PLR